RIGL News
Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswireSOUTH SAN...
PR Newswire
Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026 Rigel Highlights New GAVRETO (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026PR NewswireSOUTH SAN...
PR Newswire
Reasons Why Investors Should Consider Betting on Arvinas Stock
ARVN's first FDA-approved PROTAC degrader validates its technology, while a diverse pipeline targeting cancer and neurological disorders offers further growth potential.
Zacks
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR NewswireSOUTH SAN FRANCISCO, Calif., Oct. 2, 2026SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire...
PR Newswire
EVP & Chief Financial Officer At Rigel Pharmaceuticals Exercises Options Worth $123K
A large exercise of company stock options by Dean Schorno, EVP & Chief Financial Officer at Rigel Pharmaceuticals (NASDAQ:RIGL) was disclosed in a new SEC filing on September 3, as part of an insider exercise.
Whatread more...
Benzinga
Rigel to Participate in Upcoming September Investor Conferences
Rigel to Participate in Upcoming September Investor Conferences Rigel to Participate in Upcoming September Investor Conferences PR Newswire SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial...
PR Newswire
Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PR Newswire SOUTH SAN...
PR Newswire
Rigel Pharmaceuticals (RIGL) Q2 Earnings Miss Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -3.30% and +14.58%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rigel Reports Second Quarter 2026 Financial Results
Rigel Reports Second Quarter 2026 Financial Results Rigel Reports Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., Aug. 4, 2026 Second quarter 2026 total revenues of $78.7 million, including net product sales of $67.0 million and contract revenues from collaborations...
PR Newswire
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results
Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PR Newswire SOUTH SAN FRANCISCO, Calif., July 28, 2026 SOUTH SAN FRANCISCO, Calif., July 28, 2026 /PRNewswire...
PR Newswire
Bioventus (BVS) Soars 12.4%: Is Further Upside Left in the Stock?
Bioventus (BVS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Zacks